Reclassification of serous ovarian carcinoma by a 2-tier system: A Gynecologic Oncology Group study

Cancer

Volumn 118, Issue 12, 2012, Pages 3087-3094

  Bodurka, Diane C ^a   Deavers, Michael T ^a   Tian, Chunqiao ^b   Sun, Charlotte C ^a   Malpica, Anais ^a   Coleman, Robert L ^a   Lu, Karen H ^a   Sood, Anil K ^a   Birrer, Michael J ^c   Ozols, Robert ^d   Baergen, Rebecca ^e   Emerson, Robert E ^f   Steinhoff, Margaret ^g   Behmaram, Behnaz ^h   Rasty, Golnar ⁱ   Gershenson, David M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e WEILL CORNELL MEDICAL CENTER   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g WOMEN AND INFANTS HOSPITAL   (United States)

^h MEDICAL COLLEGE OF WISCONSIN   (United States)

ⁱ UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

2 tier grading system; Figo grading; Ovarian cancer; Serous histology

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL;

2 TIER GRADING SYSTEM; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; CLINICAL CLASSIFICATION; FEMALE; HUMAN; INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS 3 TIER SYSTEM; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SEROUS OVARIAN CARCINOMA;

ADULT; AGED; CLASSIFICATION; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM GRADING; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 84861896210     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26618     Document Type: Article

References (24)

1. Baak JP, Delemarre JF, Langley FA, Talerman A. Grading ovarian tumors. Evaluation of decision making by different pathologists. Anal Quant Histol. 1986;8:349-353. (Pubitemid 17230733)
2. Bertelsen K, Holund B, Anderson E. Reproducibility and prognostic value of histologic type and grade in early epithelial ovarian cancer. Int J Gynecol Cancer. 1993;3:72-79. (Pubitemid 23209540)
3. Shimizu Y, Kamoi S, Amada S, Akiyama F, Silverberg SG. Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer. 1998;82:893-901. (Pubitemid 28104169)
4. Winter WE III, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:3621-3627. (Pubitemid 47372600)
5. Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a 2-tier system. Am J Surg Pathol. 2004;28:496-504. (Pubitemid 38436523)
6. Malpica A, Deavers MT, Tornos C, et al. Interobserver and intraobserver variability of a 2-tier system for grading ovarian serous carcinoma. Am J Surg Pathol. 2007;31:1168-1174. (Pubitemid 47207118)
7. Gershenson DM, Sun CC, Lu KH, et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006;2:361-368. (Pubitemid 44305678)
8. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;17:3194-3200. (Pubitemid 46606249)
9. Odicino F, Pecorelli S, Zigliani L, Creasman WT. History of the FIGO cancer staging system. Int J Gynaecol Obstet. 2008;101:205-210.
10. Fink A. How to Manage, Analyze, and Interpret Survey Data. 2nd ed. Thousand Oaks, CA: Sage Publications; 2002.
11. Collett D. Modeling Survival Data in Medical Research. 2nd ed. New York, NY: Chapman & Hall/CRC; 2003.
12. Stalsberg H, Abeler V, Blom GP, Bostad L, Skarland E, Westqaard G. Observer variation in histologic classification of malignant and borderline ovarian tumors. Hum Pathol. 1988;19:1030-1035.
13. Ishioka S, Sagae S, Terasawa K, et al. Comparison of the usefulness between a new universal grading system for epithelial ovarian cancer and the FIGO grading system. Gynecol Oncol. 2003;89:447-452. (Pubitemid 36687791)
14. Seidman JD, Horkayne-Szakaly I, Cosin JA, et al. Testing of 2 binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum. Gynecol Oncol. 2005;103:703-708. (Pubitemid 44602191)
15. Bonome T, Lee JY, Park DC, et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 2005;65:10602-10612. (Pubitemid 41743756)
16. Jazaeri AA, Lu K, Schmandt R, et al. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol Carcinog. 2003;36:53-59. (Pubitemid 36183896)
17. Meinhold-Heerlein I, Bauerschlag D, Hilpert F, et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene. 2005;24:1053-1065. (Pubitemid 40313882)
18. Sieben NL, Macropoulos P, Roemen GM, et al. In ovarian neoplasms, BRAF, but not KRAS, mutations and restricted to low-grade serous tumours. J Pathol. 2004;202:336-340. (Pubitemid 38325243)
19. Singer G, Oldt R III, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003;95:484-486. (Pubitemid 36432423)
20. Singer G, Shih IeM, Truskinovsky A, Umudum H, Kurman RJ. Mutational analysis of K-ras segregates ovarian serous carcinomas into 2 types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor). Int J Gynecol Pathol. 2003;22:37-41. (Pubitemid 36014274)
21. Vang R, Shih IeM, Salani R, Sugar E, Ayhan A, Kurman R. Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data. Am J Surg Pathol. 2008;32:1667-1674.
22. O'Neill CJ, Deavers MT, Malpica A, Foster H, McCluggage WG. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol. 2005;29:1034-1041. (Pubitemid 41045547)
23. Singer G, Storh R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 2005;29:218-224. (Pubitemid 40170640)
24. Wong KK, Lu KH, Malpica A, et al. Significantly greater expression of ER, PR and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Int J Gynecol Pathol. 2007;26:404-409. (Pubitemid 47476325)